On June 1, 2020, the FDA issued a RFI soliciting stakeholder input on the listing of patent information in the Orange Book, including on the types of patent currently listed and how changes to current patent listing practices may impact drug product development. Please send any feedback to advocacy@amcp.org by August 14, 2020.
AMCP joined with national pharmacy stakeholder organizations in issuing a statement of commitment to advocate against racial injustice and all forms of discrimination and to work to eliminate the resulting inequities in patient care.
AMCP submitted comments on CMS’s interim final rule making changes to the Medicare Advantage and Part D programs in response to the COVID-19 public health emergency focused on the provision of telehealth services to Medicare beneficiaries.
AMCP webinar that addressed what is currently being seen in the industry and how to effectively support and continue this early, meaningful, and effective exchange of information for pre-approval products.
Representative organizations of America’s pharmaceutical supply and payment chain released new policy principles to promote undisrupted patient access to medications during the COVID-19 pandemic.
